甲状腺癌患者接受与未接受放射性碘治疗匹配队列的第二原发恶性肿瘤风险:基于观察性健康数据科学与信息学的分析
该回顾性倾向性匹配队列研究通过观察性健康数据科学与信息学(OHDSI)网络在韩国4家医院构建甲状腺癌(TC)患者队列,比较接受放射性碘(RAI)治疗者与未接受RAI治疗者的第二原发恶性肿瘤(SPM)风险。共纳入24,318例患者,每组各分析5,374例(平均年龄48.9岁与49.2岁,女性79.4%与79.5%)。按甲状腺癌分期、风险时间段、SPM亚型及初始年龄分层分析,RAI治疗组SPM风险的所有风险比(HR)的95%CI均≤1;结论为接受I-131治疗的TC患者与倾向性匹配的未接受I-131治疗TC患者之间SPM风险无显著差异。
要点
- 在倾向性匹配的甲状腺癌患者中,接受RAI治疗者与未接受RAI治疗者的第二原发恶性肿瘤风险无显著差异。
- 按甲状腺癌分期、风险时间段、SPM亚型及初始年龄分层分析,RAI治疗组SPM风险的所有HR的95%CI均≤1。
- 接受超过3.7 GBq I-131治疗的患者与接受低于3.7 GBq I-131治疗的患者相比,目标组内HR未显著升高(<1),基于95%CI。
核心结论
- 接受I-131治疗的甲状腺癌患者与倾向性匹配的未接受I-131治疗的甲状腺癌患者之间,第二原发恶性肿瘤风险无显著差异。
研究设计与样本
- 回顾性倾向性匹配队列研究,通过观察性健康数据科学与信息学(OHDSI)在韩国4家医院构建队列,电子健康记录转换为通用数据模型数据。
- 接受RAI治疗的甲状腺癌患者为目标组,未接受RAI治疗的甲状腺癌患者为对照组,采用1:1倾向性评分匹配。
- 共纳入24,318例患者,每组各分析5,374例;目标组与对照组平均年龄分别为48.9岁与49.2岁,女性分别为79.4%与79.5%。
- 采用Cox比例风险模型计算风险比(HR)评估SPM风险,并进行Meta分析合并HR。
主要发现
- 按甲状腺癌分期、风险时间段、SPM亚型(血液系统或非血液系统)及初始年龄(<30岁或≥30岁)进行完整或亚组分析,RAI治疗组SPM风险的所有HR的95%CI均≤1。
- 目标组内,接受超过3.7 GBq I-131治疗的患者与接受低于3.7 GBq I-131治疗的患者相比,HR未显著升高(<1),基于95%CI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Risk of second primary malignancy (SPM) after radioiodine (RAI) therapy has been continuously debated. The aim of this study is to identify the risk of SPM in thyroid cancer (TC) patients with RAI compared with TC patients without RAI from matched cohort. METHODS: Retrospective propensity-matched cohorts were constructed across 4 hospitals in South Korea via the Observational Health Data Science and Informatics (OHDSI), and electrical health records were converted to data of common data model. TC patients who received RAI therapy constituted the target group, whereas TC patients without RAI therapy constituted the comparative group with 1:1 propensity score matching. Hazard ratio (HR) by Cox proportional hazard model was used to estimate the risk of SPM, and meta-analysis was performed to pool the HRs. RESULTS: Among a total of 24,318 patients, 5,374 patients from each group were analyzed (mean age 48.9 and 49.2, women 79.4% and 79.5% for target and comparative group, respectively). All hazard ratios of SPM in TC patients with RAI therapy were ≤ 1 based on 95% confidence interval(CI) from full or subgroup analyses according to thyroid cancer stage, time-at-risk period, SPM subtype (hematologic or non-hematologic), and initial age (< 30 years or ≥ 30 years). The HR within the target group was not significantly higher (< 1) in patients who received over 3.7 GBq of I-131 compared with patients who received less than 3.7 GBq of I-131 based on 95% CI. CONCLUSION: There was no significant difference of the SPM risk between TC patients treated with I-131 and propensity-matched TC patients without I-131 therapy.
引用
- Kim S, Bang JI, Boo D, et al. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur J Nucl Med Mol Imaging. 2022. PMID: 35362796. doi:10.1007/s00259-022-05779-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。